Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

724 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study.
Tauber M, Buche S, Reygagne P, Berthelot JM, Aubin F, Ghislain PD, Cohen JD, Coquerelle P, Goujon E, Jullien D, Brixi H, Jeudy G, Guennoc X, Martin A, Brénaut E, Hoppé E, Bertolotti A, Bardin T, Delaporte E, Allez M, Bachelez H, Seneschal J, Viguier M; Groupe de Recherche sur Psoriasis de Société Française de, Dermatologie; Club Rhumatismes et Inflammation (CRI); Groupe d'études thérapeutiques des affections inflammatoires du tube digestif (GETAID). Tauber M, et al. Among authors: delaporte e. J Am Acad Dermatol. 2014 Jun;70(6):1146-9. doi: 10.1016/j.jaad.2014.03.005. J Am Acad Dermatol. 2014. PMID: 24831323 No abstract available.
Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
Faivre C, Villani AP, Aubin F, Lipsker D, Bottaro M, Cohen JD, Durupt F, Jeudy G, Sbidian E, Toussirot E, Badot V, Barbarot S, Debarbieux S, Delaporte E, Goegebeur G, Morel J, Nassif A, Duru G, Jullien D; French Society of Dermatology and Club Rheumatisms and Inflammation. Faivre C, et al. Among authors: delaporte e. J Am Acad Dermatol. 2016 Jun;74(6):1153-9. doi: 10.1016/j.jaad.2016.01.018. Epub 2016 Mar 8. J Am Acad Dermatol. 2016. PMID: 26965410
Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
Viguier M, Pagès C, Aubin F, Delaporte E, Descamps V, Lok C, Beylot-Barry M, Séneschal J, Dubertret L, Morand JJ, Dréno B, Bachelez H; Groupe Français de Recherche sur le Psoriasis. Viguier M, et al. Among authors: delaporte e. Br J Dermatol. 2012 Aug;167(2):417-23. doi: 10.1111/j.1365-2133.2012.10940.x. Epub 2012 Jun 11. Br J Dermatol. 2012. PMID: 22413927
Predictors of long-term drug survival for infliximab in psoriasis.
Magis Q, Jullien D, Gaudy-Marqueste C, Baumstark K, Viguier M, Bachelez H, Guibal F, Delaporte E, Karimova E, Montaudié H, Boye T, Aubin F, Beylot-Barry M, Richard MA; “Groupe de Recherche sur le Psoriasis de la Société Française”. Magis Q, et al. Among authors: delaporte e. J Eur Acad Dermatol Venereol. 2017 Jan;31(1):96-101. doi: 10.1111/jdv.13747. Epub 2016 Jun 21. J Eur Acad Dermatol Venereol. 2017. PMID: 27325600
Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
Viguier M, Aubin F, Delaporte E, Pagès C, Paul C, Beylot-Barry M, Goujon C, Rybojad M, Bachelez H; Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie. Viguier M, et al. Among authors: delaporte e. Arch Dermatol. 2012 Dec;148(12):1423-5. doi: 10.1001/2013.jamadermatol.80. Arch Dermatol. 2012. PMID: 23247492 No abstract available.
Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort.
Sbidian E, Giboin C, Bachelez H, Paul C, Beylot-Barry M, Dupuy A, Viguier M, Lacour JP, Schmutz JL, Bravard P, Mahé E, Beneton N, Misery L, Delaporte E, Modiano P, Barbarot S, Regnier E, Jullien D, Richard MA, Joly P, Tubach F, Chosidow O. Sbidian E, et al. Among authors: delaporte e. J Eur Acad Dermatol Venereol. 2017 Dec;31(12):2046-2054. doi: 10.1111/jdv.14406. Epub 2017 Jul 16. J Eur Acad Dermatol Venereol. 2017. PMID: 28609574 Free article.
Skin side effects of inflammatory bowel disease therapy.
Torres J, Buche S, Delaporte E, Colombel JF. Torres J, et al. Among authors: delaporte e. Inflamm Bowel Dis. 2013 Apr;19(5):1086-98. doi: 10.1097/MIB.0b013e3182802c07. Inflamm Bowel Dis. 2013. PMID: 23474780 Review.
Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.
Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, Papay P, Allez M, Cosnes J, Cortot A, Laharie D, Reimund JM, Lémann M, Delaporte E, Colombel JF; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Rahier JF, et al. Among authors: delaporte e. Clin Gastroenterol Hepatol. 2010 Dec;8(12):1048-55. doi: 10.1016/j.cgh.2010.07.022. Epub 2010 Aug 20. Clin Gastroenterol Hepatol. 2010. PMID: 20728573 Free article.
724 results